Comparative Pharmacology
Head-to-head clinical analysis: COTRIM D S versus VIBATIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COTRIM D S versus VIBATIV.
COTRIM D.S. vs VIBATIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COTRIM D.S. is a combination of sulfamethoxazole, a competitive inhibitor of dihydropteroate synthase, and trimethoprim, a reversible inhibitor of dihydrofolate reductase. This sequential blockade of folate synthesis leads to bactericidal activity.
Lipoglycopeptide antibiotic that inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation. Also disrupts membrane potential and increases membrane permeability.
160 mg trimethoprim / 800 mg sulfamethoxazole (one double-strength tablet) orally every 12 hours.
10 mg/kg intravenously once every 24 hours, infused over 60 minutes for 7 to 14 days.
None Documented
None Documented
Sulfamethoxazole: 9-12 hours (normal renal function). Trimethoprim: 8-11 hours. Both are prolonged in renal impairment (e.g., creatinine clearance <30 mL/min: >24 hours). Clinical context: dosing interval is typically 12 hours; dose adjustment required if CrCl <30 mL/min.
Terminal elimination half-life is approximately 177 hours (7.4 days), supporting once-daily dosing.
Sulfamethoxazole: ~20% unchanged in urine, remainder as acetylated and glucuronide metabolites. Trimethoprim: ~50-80% unchanged in urine, remainder as oxidative metabolites. Both undergo renal excretion via glomerular filtration and tubular secretion. Total renal elimination: 70-90% of dose combined. Biliary/fecal: <10%.
Primarily renal excretion as unchanged drug (approximately 93% of dose recovered in urine; <5% in feces).
Category C
Category C
Antibiotic
Antibiotic